MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Company Info
- Quarterly Company Results - June 2018
"Pharmaceuticals" Company Results for June 2018 Quarter 
Here are the latest quarterly results of India's top pharmaceuticals companies. For more detailed updates, read our pharmaceuticals sector report and check the latest pharmaceuticals sector stock quotes.
| Click on title to sort | Jun 2017 | Jun 2018 | YoY %-Change | Get More Info | ||||
|---|---|---|---|---|---|---|---|---|
Name |
Net Sales (Rs m) |
PAT (Rs m) |
Net Sales (Rs m) |
PAT (Rs m) |
Net Sales (%) |
PAT (%) |
P/E* (x) |
|
| ABBOTT INDIA | 7,147 | 483 | 8,449 | 824 | 18.2% | 70.8% | 56.5 | More Info
|
| AJANTA PHARMA | 4,731 | 948 | 5,110 | 1,058 | 8.0% | 11.6% | 26.7 | More Info
|
| ALEMBIC LTD | 296 | 33 | 445 | 69 | 50.4% | 106.9% | 46.5 | More Info
|
| ALEMBIC PHARMA | 6,482 | 634 | 8,625 | 904 | 33.1% | 42.6% | 13.8 | More Info
|
| ASTRAZENECA PHARMA | 1,285 | 58 | 1,614 | 64 | 25.7% | 10.3% | 80.3 | More Info
|
| AUROBINDO PHARMA | 36,788 | 5,170 | 42,503 | 4,552 | 15.5% | -12.0% | 8.7 | More Info
|
| BIOCON | 9,337 | 936 | 11,238 | 1,378 | 20.4% | 47.2% | 25.3 | More Info
|
| CADILA HEALTHCARE | 22,288 | 1,182 | 28,937 | 4,425 | 29.8% | 274.4% | 22.7 | More Info
|
| CIPLA | 35,251 | 4,258 | 39,390 | 4,456 | 11.7% | 4.7% | 21.6 | More Info
|
| DIVIS LABORATORIES | 8,212 | 1,765 | 9,953 | 2,662 | 21.2% | 50.8% | 39.6 | More Info
|
| DR. REDDYS LAB | 33,332 | 666 | 37,365 | 4,761 | 12.1% | 614.9% | 31.8 | More Info
|
| FDC LTD. | 2,448 | 293 | 2,857 | 511 | 16.7% | 74.5% | 15.7 | More Info
|
| GLENMARK PHARMA | 23,630 | 3,334 | 21,656 | 2,330 | -8.4% | -30.1% | 8.4 | More Info
|
| GSK PHARMA | 6,071 | 264 | 7,357 | 886 | 21.2% | 235.3% | 217.8 | More Info
|
| INDOCO REMEDIES | 2,090 | -217 | 2,175 | -120 | 4.1% | N.A. | 64.7 | More Info
|
| INDRAPRASTHA MEDICAL | 1,842 | 48 | 1,894 | 65 | 2.8% | 36.2% | 7.7 | More Info
|
| IPCA LABS | 7,130 | -203 | 8,539 | 655 | 19.8% | N.A. | 27.6 | More Info
|
| J.B.CHEMICALS | 2,838 | 204 | 3,660 | 421 | 28.9% | 106.6% | 14.6 | More Info
|
| LUPIN | 24,993 | 3,541 | 38,559 | 2,023 | 54.3% | -42.9% | N.A. | More Info
|
| NATCO PHARMA | 4,453 | 937 | 5,386 | 1,811 | 21.0% | 93.3% | 17.7 | More Info
|
| NOVARTIS | 1,148 | 70 | 1,381 | 100 | 20.3% | 42.2% | 760.9 | More Info
|
| ORCHID PHARMA LTD | 1,396 | -1,145 | 1,306 | -460 | -6.4% | N.A. | N.A. | More Info
|
| PANACEA BIOTECH | 1,076 | -480 | 951 | -368 | -11.6% | N.A. | 5.7 | More Info
|
| PFIZER | 4,326 | 572 | 5,123 | 918 | 18.4% | 60.6% | 35.7 | More Info
|
| PIRAMAL ENTERPRISES | 22,541 | 2,475 | 29,025 | -1,300 | 28.8% | -152.5% | 8.4 | More Info
|
| PROCTER & GAMBLE HEALTH | 2,657 | 201 | 2,203 | 328 | -17.1% | 63.1% | 40.4 | More Info
|
| SANOFI INDIA | 6,006 | 737 | 6,836 | 996 | 13.8% | 35.1% | 38.7 | More Info
|
| STRIDES PHARMA SCIENCE | 8,418 | 88 | 6,635 | 38 | -21.2% | -57.5% | 4.8 | More Info
|
| SUN PHARMA | 62,088 | -3,207 | 72,242 | 11,101 | 16.4% | N.A. | 20.5 | More Info
|
| SUVEN LIFESCIENCES | 1,410 | 296 | 1,917 | 388 | 35.9% | 31.4% | 1.4 | More Info
|
| TORRENT PHARMA | 13,740 | 1,880 | 18,720 | 1,630 | 36.2% | -13.3% | 62.9 | More Info
|
| TTK HEALTHCARE | 1,254 | -45 | 1,731 | 79 | 38.1% | N.A. | 16.3 | More Info
|
| UNICHEM LAB | 3,141 | 15 | 2,014 | -207 | -35.9% | -1479.6% | N.A. | More Info
|
| VENUS REMEDIES | 782 | 8 | 655 | -56 | -16.2% | -756.1% | N.A. | More Info
|
| WOCKHARDT | 8,911 | -4,626 | 10,077 | -862 | 13.1% | N.A. | N.A. | More Info
|
| Sector Aggregate | 379,538 | 21,173 | 446,529 | 46,059 | 17.7% | 117.5% | ||
* Trailing 12 months earnings, excluding extraordinary / exceptional items. |
||||||||
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.